Patents Assigned to DFB Pharmaceuticals, Inc.
-
Patent number: 7700351Abstract: Disclosed is a kit comprising a first component comprising fibrinogen, aprotinin, and a buffered solution, and a second component comprising, fibroblasts, keratinocytes, thrombin, glycerol, human serum albumin, and a buffered solution, wherein the first and second components are comprised in separate sterile containers.Type: GrantFiled: October 21, 2008Date of Patent: April 20, 2010Assignee: DFB Pharmaceuticals, Inc.Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Publication number: 20100068281Abstract: Disclosed is a composition comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6, IL-8, TGF?, and TNF? and an extracellular matrix comprising alginate, wherein the cells are allogeneic and mitotically inactive.Type: ApplicationFiled: September 18, 2009Publication date: March 18, 2010Applicant: DFB PHARMACEUTICALS, INC.Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Publication number: 20090257986Abstract: The present invention relates to the treatment of skin defects by organotypically-cultured autologous keratinocytes isolated from the outer root sheath of anagen or growing hair. Methods for primary, as well as subsequent organotypic cultures (i.e., epidermal equivalents) in fully-defined media supplemented by autologous human serum and substances isolated form blood components, with minimal allogeneic biological supplements, are disclosed herein. Techniques to prepare epidermal equivalents for transplantation by use of a biocompatible glue are also disclosed herein.Type: ApplicationFiled: January 14, 2009Publication date: October 15, 2009Applicant: DFB Pharmaceuticals, Inc.Inventors: Thomas Hunziker, Alain Limat
-
Publication number: 20090232791Abstract: Disclosed is a kit comprising a first component comprising fibrinogen, aprotinin, and a buffered solution, and a second component comprising, fibroblasts, keratinocytes, thrombin, glycerol, human serum albumin, and a buffered solution, wherein the first and second components are comprised in separate sterile containers.Type: ApplicationFiled: October 21, 2008Publication date: September 17, 2009Applicant: DFB PHARMACEUTICALS, INC.Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Patent number: 7449333Abstract: The present invention provides the use and composition of matter of angiogenic or other growth/cytokine factors expressed by mixtures of allogeneic human cell strains or lines of various types and stages of differentiation. Also provided are unencapsulated preparations (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) for the purpose of temporary application to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.Type: GrantFiled: September 5, 2003Date of Patent: November 11, 2008Assignee: DFB Pharmaceuticals, Inc.Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Publication number: 20060292126Abstract: The present invention relates to the treatment of skin defects by organotypically-cultured autologous keratinocytes isolated from the outer root sheath of anagen or growing hair. Methods for primary, as well as subsequent organotypic cultures (i.e., epidermal equivalents) in fully-defined media supplemented by autologous human serum and substances isolated form blood components, with minimal allogeneic biological supplements, are disclosed herein. Techniques to prepare epidermal equivalents for transplantation by use of a biocompatible glue are also disclosed herein.Type: ApplicationFiled: October 31, 2005Publication date: December 28, 2006Applicant: DFB Pharmaceuticals, Inc.Inventors: Thomas Hunziker, Alain Limat
-
Patent number: 7144729Abstract: The present invention provides the use and composition of matter of angiogenic or other growth/cytokine factors expressed by mixtures of allogeneic human cell strains or lines of various types and stages of differentiation. Also provided are unencapsulated preparations (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) for the purpose of temporary application to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.Type: GrantFiled: December 19, 2002Date of Patent: December 5, 2006Assignee: DFB Pharmaceuticals, Inc.Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Publication number: 20060240555Abstract: The present invention relates to fibrin cell supports for cell cultures formed by the mixture of plasma proteins including fibrinogen and thrombin. The fibrin cell supports are preferably used for preparing a culture of cells such as keratinocytes, recovering the culture in the form of a reconstituted tissue, and transporting same. The reconstituted tissue is particularly suitable for use as a skin graft.Type: ApplicationFiled: February 24, 2006Publication date: October 26, 2006Applicant: DFB Pharmaceuticals, Inc.Inventor: Vincent Ronfard
-
Publication number: 20060134093Abstract: The present invention relates to fibrin cell supports for cell cultures formed by the mixture of plasma proteins including fibrinogen and thrombin. The fibrin cell supports are preferably used for preparing a culture of cells such as keratinocytes, recovering the culture in the form of a reconstituted tissue, and transporting same. The reconstituted tissue is particularly suitable for use as a skin graft.Type: ApplicationFiled: September 5, 2003Publication date: June 22, 2006Applicant: DFB Pharmaceuticals, Inc.Inventor: Vincent Ronfard
-
Patent number: 7014849Abstract: The present invention relates to the treatment of skin defects by organotypically-cultured autologous keratinocytes isolated from the outer root sheath of anagen or growing hair. Methods for primary, as well as subsequent organotypic cultures (i.e., epidermal equivalents) in fully-defined media supplemented by autologous human serum and substances isolated form blood components, with minimal allogeneic biological supplements, are disclosed herein. Techniques to prepare epidermal equivalents for transplantation by use of a biocompatible glue are also disclosed herein.Type: GrantFiled: July 20, 2000Date of Patent: March 21, 2006Assignee: DFB Pharmaceuticals, Inc.Inventors: Thomas Hunziker, Alain Limat